From Wikipedia, the free encyclopedia
|Molar mass||143.1 kg/mol|
|(what is this?)|
Drozitumab is a human monoclonal antibody designed for the treatment of cancers.
Drozitumab was developed by Genentech.
Adverse drug effects
|This section is empty. You can help by adding to it. (October 2014)|
- "Statement On A Nonproprietary Name Adopted By The USAN Council: Drozitumab" (PDF). American Medical Association.
|This monoclonal antibody-related article is a stub. You can help Wikipedia by expanding it.|
|This antineoplastic or immunomodulatory drug article is a stub. You can help Wikipedia by expanding it.|